Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs
Expert Rev Clin Pharmacol. 2024 Apr 17. doi: 10.1080/17512433.2024.2344669. Online ahead of print.ABSTRACTINTRODUCTION: Single-arm trials (SATs) and surrogate endpoints were adopted as pivotal evidence for accelerated approval of anticancer drugs for more than 30 years. However, concerns regarding clinical evidence quality in trials, particularly in the SATs of anticancer drugs have increasingly been raised. SAT may not always provide strong evidence due to the lack of control and endpoint of overall survival that is typically present in randomized controlled trials.AREAS COVERED: Clinical trial endpoint adjudication is a ...
Source: Pharmacological Reviews - April 18, 2024 Category: Drugs & Pharmacology Authors: Yafang Huang Jinqiu Yuan Source Type: research
Effectiveness of statins in people living with HIV: a systematic review and meta-analysis of randomized controlled trials
CONCLUSION: When considered collectively, statin therapy's advantages appear to exceed its occasional predictable side effects like liver or muscle toxicity.REGISTRATION: PROSPERO registration ID: CRD42023469521.PMID:38629133 | DOI:10.1080/17512433.2024.2344672 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 17, 2024 Category: Drugs & Pharmacology Authors: Sai Santhosha Mrudula Alla Dhruv J Shah Vysakh Ratheesh Deekshitha Alla Thanmayee Tummala Moksh S Khetan Ritika J Shah Ruth G Bayeh Mahek Fatima Sanah K Ahmed Mert Sab ıroğlu Source Type: research
The Association between Use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis
CONCLUSION: In summary, while renin-angiotensin-aldosterone system inhibitors did not appear to impact PC risk, their use was associated with lower PC mortality based on this meta-analysis of the current evidence. More rigorous and well-designed studies are required to validate and support these findings.PMID:38629353 | DOI:10.2174/0127724328291047240409062436 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 17, 2024 Category: Drugs & Pharmacology Authors: Rasoul Rahimi Seyed Mahmood Reza Hashemi Rafsanjani Saeid Heidari-Soureshjani Catherine Mt Sherwin Karamali Kasiri Source Type: research
Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future
We describe how such a program can be designed and implemented.PMID:38629382 | DOI:10.1080/17512433.2024.2344665 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 17, 2024 Category: Drugs & Pharmacology Authors: Maurlia D Upchurch Benyam Muluneh Source Type: research
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia
Expert Rev Clin Pharmacol. 2024 Apr 16. doi: 10.1080/17512433.2024.2343915. Online ahead of print.ABSTRACTINTRODUCTION: Opioids are commonly used for perioperative analgesia, yet children still suffer high rates of severe post-surgical pain and opioid-related adverse effects. Persistent and severe acute surgical pain greatly increases the child's chances of chronic surgical pain, long-term opioid use, and opioid use disorder.AREAS COVERED: Enhanced recovery after surgery (ERAS) protocols, are often inadequate in treating a child's severe surgical pain. Research suggests that 'older' and longer-acting opioids such as methad...
Source: Pharmacological Reviews - April 16, 2024 Category: Drugs & Pharmacology Authors: Yun Han Chen Anastasios Xenitidis Paul Hoffman Leslie Matthews Swathi G Padmanabhan Lakshmi Aravindan Ruth Ressler Inesh Sivam Sahana Sivam Chase F Gillispie Senthilkumar Sadhasivam Source Type: research
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia
Expert Rev Clin Pharmacol. 2024 Apr 16. doi: 10.1080/17512433.2024.2343915. Online ahead of print.ABSTRACTINTRODUCTION: Opioids are commonly used for perioperative analgesia, yet children still suffer high rates of severe post-surgical pain and opioid-related adverse effects. Persistent and severe acute surgical pain greatly increases the child's chances of chronic surgical pain, long-term opioid use, and opioid use disorder.AREAS COVERED: Enhanced recovery after surgery (ERAS) protocols, are often inadequate in treating a child's severe surgical pain. Research suggests that 'older' and longer-acting opioids such as methad...
Source: Pharmacological Reviews - April 16, 2024 Category: Drugs & Pharmacology Authors: Yun Han Chen Anastasios Xenitidis Paul Hoffman Leslie Matthews Swathi G Padmanabhan Lakshmi Aravindan Ruth Ressler Inesh Sivam Sahana Sivam Chase F Gillispie Senthilkumar Sadhasivam Source Type: research
Engaging patients in conversations about deprescribing
Expert Rev Clin Pharmacol. 2024 Apr 15. doi: 10.1080/17512433.2024.2343913. Online ahead of print.NO ABSTRACTPMID:38618915 | DOI:10.1080/17512433.2024.2343913 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 15, 2024 Category: Drugs & Pharmacology Authors: Barbara Farrell Source Type: research
Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review
Expert Rev Clin Pharmacol. 2024 Apr 15. doi: 10.1080/17512433.2024.2343875. Online ahead of print.ABSTRACTINTRODUCTION: Drug-drug interactions (DDIs) are defined as the pharmacological effects produced by the concomitant administration of two or more drugs. To minimize false positive signals and ensure their validity when analyzing Spontaneous Reporting System (SRS) databases, it has been suggested to incorporate key pharmacological principles, such as temporal plausibility.AREAS COVERED: the scoping review of the literature was completed using MEDLINE from inception to March 2023. Included studies had to provide detailed ...
Source: Pharmacological Reviews - April 15, 2024 Category: Drugs & Pharmacology Authors: Marianna Cocco Carla Carnovale Emilio Clementi Maria Antonietta Barbieri Vera Battini Maurizio Sessa Source Type: research
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates
Pharmacol Rev. 2024 Apr 15:PHARMREV-AR-2023-001084. doi: 10.1124/pharmrev.123.001084. Online ahead of print.ABSTRACTIn the era of precision medicine, Antibody-Drug Conjugates (ADCs) have emerged as a cutting-edge therapeutic strategy. These innovative compounds combine the precision of monoclonal antibodies with the potent cell-killing or immune-modulating abilities of attached drug payloads. This unique strategy not only reduces off-target toxicity but also enhances the therapeutic effectiveness of drugs. Beyond their well-established role in oncology, ADCs are now showing promising potential in addressing the unmet needs...
Source: Pharmacological Reviews - April 15, 2024 Category: Drugs & Pharmacology Authors: Zhiwen Huang Zachary Braunstein Jun Chen Yingying Wei Xiaoquan Rao Lingli Dong Jixin Zhong Source Type: research
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Rev Clin Pharmacol. 2024 Apr;17(4):363-379. doi: 10.1080/17512433.2024.2340552. Epub 2024 Apr 11.ABSTRACTINTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor ne...
Source: Pharmacological Reviews - April 11, 2024 Category: Drugs & Pharmacology Authors: Laura Mateu-Arrom Lluis Puig Source Type: research
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Rev Clin Pharmacol. 2024 Apr 11:1-17. doi: 10.1080/17512433.2024.2340552. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor nec...
Source: Pharmacological Reviews - April 11, 2024 Category: Drugs & Pharmacology Authors: Laura L Mateu-Arrom Lluis L Puig Source Type: research
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Rev Clin Pharmacol. 2024 Apr 11:1-17. doi: 10.1080/17512433.2024.2340552. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor nec...
Source: Pharmacological Reviews - April 11, 2024 Category: Drugs & Pharmacology Authors: Laura L Mateu-Arrom Lluis L Puig Source Type: research
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy
Expert Rev Clin Pharmacol. 2024 Apr 3:1-10. doi: 10.1080/17512433.2024.2337012. Online ahead of print.ABSTRACTINTRODUCTION: Epilepsies are a group of heterogeneous brain disorder, and antiseizure medications (ASMs) are the mainstay of treatment. Despite the availability of more than 30 drugs, at least one third of individuals with epilepsy are drug-resistant. This emphasizes the need for novel compounds that combine efficacy with improved tolerability.AREAS COVERED: A literature review on the pharmacology, efficacy, tolerability, and safety of azetukalner (XEN1101), a second-generation opener of neuronal potassium channels...
Source: Pharmacological Reviews - April 4, 2024 Category: Drugs & Pharmacology Authors: Simona Lattanzi Eugen Trinka Stefano Meletti Pasquale Striano Sara Matricardi Mauro Silvestrini Francesco Brigo Source Type: research
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy
Expert Rev Clin Pharmacol. 2024 Apr 3:1-10. doi: 10.1080/17512433.2024.2337012. Online ahead of print.ABSTRACTINTRODUCTION: Epilepsies are a group of heterogeneous brain disorder, and antiseizure medications (ASMs) are the mainstay of treatment. Despite the availability of more than 30 drugs, at least one third of individuals with epilepsy are drug-resistant. This emphasizes the need for novel compounds that combine efficacy with improved tolerability.AREAS COVERED: A literature review on the pharmacology, efficacy, tolerability, and safety of azetukalner (XEN1101), a second-generation opener of neuronal potassium channels...
Source: Pharmacological Reviews - April 4, 2024 Category: Drugs & Pharmacology Authors: Simona Lattanzi Eugen Trinka Stefano Meletti Pasquale Striano Sara Matricardi Mauro Silvestrini Francesco Brigo Source Type: research
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy
Expert Rev Clin Pharmacol. 2024 Apr 3:1-10. doi: 10.1080/17512433.2024.2337012. Online ahead of print.ABSTRACTINTRODUCTION: Epilepsies are a group of heterogeneous brain disorder, and antiseizure medications (ASMs) are the mainstay of treatment. Despite the availability of more than 30 drugs, at least one third of individuals with epilepsy are drug-resistant. This emphasizes the need for novel compounds that combine efficacy with improved tolerability.AREAS COVERED: A literature review on the pharmacology, efficacy, tolerability, and safety of azetukalner (XEN1101), a second-generation opener of neuronal potassium channels...
Source: Pharmacological Reviews - April 4, 2024 Category: Drugs & Pharmacology Authors: Simona Lattanzi Eugen Trinka Stefano Meletti Pasquale Striano Sara Matricardi Mauro Silvestrini Francesco Brigo Source Type: research
